BEST-J score 17+

Yoichi Kakuta

Entwickelt für iPhone

    • Gratis

iPhone-Screenshots

Beschreibung

Bleeding after ESD occurs in 4.1%–8.5% of patients who undergo gastric ESD. The "BEST-J score" is a prediction model to stratify the risk of bleeding after ESD for early gastric cancers. Nine factors were weighted with point values: 4 points for anticoagulants (warfarin, direct oral anticoagulants), 3 points for chronic kidney disease with hemodialysis, 2 points each for P2Y12 receptor antagonist (thienopyridine) and aspirin, 1 point each for cilostazol, a tumor size >30 mm, lower-third in tumor location, and presence of multiple tumors, and −1 point for interruption of each kind of antithrombotic agents. The patients were categorized into four bleeding risk groups: low (0–1 points: 2.8% risk), intermediate (2 points: 6.1%), high (3–4 points: 11.4%) and very high (≥5 points: 29.7%).

*1. If an antiplatelet agent was replaced with another agent, select "Temporal discontinuation" of the original agent and "None" of the replaced agent. For example, if P2Y12 receptor antagonist is replaced with aspirin, select "Temporal discontinuation" of P2Y12 receptor antagonist and "None" of aspirin.

*2. If the patient received heparin bridging therapy, select "Temporal discontinuation" of the original agent. For example, if warfarin is bridged with heparin, select "Temporal discontinuation" of warfarin.

*3. Time of discontinuing antithrombotic agents before ESD is based on the Japanese guidelines (Dig Endosc. 2014; 26: 1-14.): aspirin, 3−5 days; P2Y12 receptor antagonist (thienopyridine), 5−7 days; cilostazol, 1 day; warfarin, 3−5 days; DOAC, 1−2 days.


For more information, see the reference below.
Gut. 2020 [Epub ahead of print]
A prediction model of bleeding after endoscopic submucosal dissection for early gastric cancer: BEST-J score.
Hatta W, Tsuji Y, Yoshio T, Kakushima N, Hoteya S, Doyama H, Nagami Y, Hikichi T, Kobayashi M, Morita Y, Sumiyoshi T, Iguchi M, Tomida H, Inoue T, Koike T, Mikami T, Hasatani K, Nishikawa J, Matsumura T, Nebiki H, Nakamatsu D, Ohnita K, Suzuki H, Ueyama H, Hayashi Y, Sugimoto M, Yamaguchi S, Michida T, Yada T, Asahina Y, Narasaka T, Kuribayashi S, Kiyotoki S, Mabe K, Nakamura T, Nakaya N, Fujishiro M, Masamune A.


You can view the application help by tapping a title bar.

DISCLAIMER: This application is intended for educational or research purposes only. It does not create any patient-physician relationship, and should not be used as a substitute for professional diagnosis and treatment.

[Developer]
2020 東北大学病院消化器内科・大腸グループ
2020 Kenichi Negoro, MD, PhD
2020 Yoichi Kakuta, MD, PhD
2020 Waku Hatta, MD, PhD (Consultant)
2020 Xiaoyi Jin, MD, PhD (Translation)
http://www.gastroente.med.tohoku.ac.jp/
tohoku.ibd@gmail.com

App-Datenschutz

Der Entwickler, Yoichi Kakuta, hat Apple keine Details über die eigenen Datenschutzrichtlinien und den Umgang mit Daten bereitgestellt. Weitere Informationen findest du in den Datenschutzrichtlinien des Entwicklers.

Keine Details angegeben

Der Entwickler muss bei der Übermittlung seiner nächsten App-Aktualisierung Angaben zum Datenschutz machen.

Mehr von diesem Entwickler

Geno-P
Bildung
eCura
Gesundheit und Fitness
IBD-QR
Medizin
CHAMPS score
Gesundheit und Fitness

Das gefällt dir vielleicht auch

第107回日本消化器内視鏡学会総会
Medizin
第105回日本消化器内視鏡学会総会
Medizin
肝炎治療GL
Medizin
JPN GL 2021
Medizin
肝硬変重症度Child分類・消化器癌進行度分類
Medizin
日本胃癌学会総会
Medizin